相关实验视频
Updated: Jul 15, 2025

Genetic Analysis of Hereditary Transthyretin Ala97Ser Related Amyloidosis
Published on: June 9, 2018
治疗多神经病的遗传性转基因粉症
Teresa Coelho1, Wilson Marques2, Noel R Dasgupta3
1Centro Hospitalar Universitário de Santo António, Porto, Portugal.
艾普隆特森显著降低了血清中氨酸度,改善了遗传性氨酸氨酸多性神经病患者的神经病变和生活质量. 这种基因沉默疗法提供了一个有前途的新疗法.
科学领域:
- 神经学
- 遗传学
- 药理学
背景情况:
- 遗传性转基因粉症 (ATTRv) 是一种渐进的衰弱性疾病.
- 对于ATTRv来说,静止基因是一种新的治疗方法.
- 埃普隆特森是一种针对TTR基因表达的试验性联体结合抗意义寡核酸.
研究的目的:
- 评估eplontersen在ATTRv多神经病变患者中的疗效和安全性.
- 评估eplontersen对神经病变和生活质量的影响.
主要方法:
- 这项NEURO- TTRansform试验是一项开放式的3期研究,涉及168名患有ATTRv多神经病的成年人.
- 患者接受皮下eplontersen (45毫克每4周),并与之前的安慰剂组进行比较.
- 主要终点包括血清中松素度的变化,修改的神经病障评分+7 (mNIS+7),以及诺福克糖尿病神经病质问卷 (Norfolk QoL- DN) 在65/ 66周的评分.
主要成果:
- 在第65周,Eplontersen显示血清中松素减少了81. 7%,而安慰剂则降低了11. 2%.
- 与安慰剂相比,用eplontersen治疗的患者在mNIS+7 (0. 3vs25. 1) 和Norfolk QoL- DN (- 5. 5vs14. 2) 评分上显著改善.
- 导致停药的不良事件很少 (4%用于eplontersen,3%用于安慰剂),严重不良事件或死亡没有显著差异.
结论:
- 治疗Eplontersen导致血清中松素水平显著降低.
- 在ATTRv多神经病患者中,Eplontersen显著改善了神经病变损伤和生活质量.
- 埃普隆特森似乎是ATTRv多神经病的安全有效治疗方案.
更多相关视频
09:39Establishing a Mouse Model of a Pure Small Fiber Neuropathy with the Ultrapotent Agonist of Transient Receptor Potential Vanilloid Type 1
Published on: February 13, 2018
09:46Isolation, Culture, and Genetic Engineering of Mammalian Primary Pigment Epithelial Cells for Non-Viral Gene Therapy
Published on: February 26, 2021
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Alzheimer's Disease: Treatment
Antiepileptic Drugs: Glutamate Antagonists